Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the HFSA 21st Annual Scientific Meeting
September 11 2017 - 4:00PM
Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional
results from COSMIC-HF (
Chronic
Oral
Study of
Myosin Activation to
Increase
Contractility in
Heart
Failure), a Phase 2 trial evaluating omecamtiv
mecarbil in patients with chronic heart failure, will be presented
in a Rapid Fire Abstracts Presentation at the 21st Annual Heart
Failure Society of America Scientific Meeting from September 16-19
in Dallas, TX.
Abstract Title: Effect of omecamtiv mecarbil in
patients with ischemic and non-ischemic heart failure with reduced
ejection fraction: Results from COSMIC-HFSpeaker: John Teerlink,
M.D., Professor of Clinical Medicine at the University of
California San Francisco and Director of Heart Failure at the San
Francisco Veterans Affairs Medical CentersSession Title: Rapid Fire
Abstracts ILocation: Gaylord Texan Hotel & Convention Center,
Grapevine 1-3Date: Sunday, September 17Time: 1:00 PM – 2:00 PM
CDT
About Omecamtiv Mecarbil
Omecamtiv mecarbil is a novel cardiac myosin
activator. Cardiac myosin is the cytoskeletal motor protein in the
cardiac muscle cell that is directly responsible for converting
chemical energy into the mechanical force resulting in cardiac
contraction. Cardiac myosin activators are thought to accelerate
the rate-limiting step of the myosin enzymatic cycle and shift the
enzymatic cycle in favor of the force-producing state. Preclinical
research has shown that cardiac myosin activators increase
contractility in the absence of changes in intracellular calcium in
cardiac myocytes.
Omecamtiv mecarbil is being developed by Amgen
in collaboration with Cytokinetics. Amgen holds an exclusive,
worldwide license to omecamtiv mecarbil and related compounds,
subject to Cytokinetics’ specified development and
commercialization rights. Amgen has also entered an alliance with
Servier for exclusive commercialization rights in Europe as well as
the Commonwealth of Independent States, including Russia. Servier
contributes funding for development and provides strategic support
to the program.
About Cytokinetics
Cytokinetics is a late-stage
biopharmaceutical company focused on discovering, developing and
commercializing first-in-class muscle activators as potential
treatments for debilitating diseases in which muscle performance is
compromised and/or declining. As a leader in muscle biology and the
mechanics of muscle performance, the company is developing small
molecule drug candidates specifically engineered to increase muscle
function and contractility. Cytokinetics’ lead drug candidate
is tirasemtiv, a fast skeletal muscle troponin activator
(FSTA). Tirasemtiv is the subject of VITALITY-ALS, an
international Phase 3 clinical trial in patients with
ALS. Tirasemtiv has been granted orphan drug designation
and fast track status by the U.S. Food and Drug
Administration (FDA) and orphan medicinal product designation
by the European Medicines Agency for the potential
treatment of ALS. Cytokinetics is preparing for the
potential commercialization of tirasemtiv in North
America and Europe and has granted an option
to Astellas Pharma Inc. (“Astellas”) for development and
commercialization in other countries. Cytokinetics is
collaborating with Astellas to develop CK-2127107, a
next-generation FSTA. CK-2127107 has been granted orphan drug
designation by the FDA for the potential treatment of
SMA. CK-2127107 is the subject of three ongoing Phase 2 clinical
trials enrolling patients with spinal muscular atrophy, chronic
obstructive pulmonary disease and ALS. Astellas is also conducting
a Phase 1b clinical trial of CK-2127107 in elderly adults with
limited mobility. Cytokinetics is collaborating
with Amgen Inc. (“Amgen”) to develop omecamtiv
mecarbil, a novel cardiac muscle activator. Omecamtiv
mecarbil is the subject of GALACTIC-HF, an international Phase
3 clinical trial in patients with heart
failure. Amgen holds an exclusive worldwide license to
develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization
in Europe and certain other countries. Astellas holds an
exclusive worldwide license to develop and commercialize
CK-2127107. Licenses held by Amgen and Astellas are
subject to Cytokinetics' specified co-development and
co-commercialization rights. For additional information
about Cytokinetics,
visit http://www.cytokinetics.com/.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements, and claims
the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to Cytokinetics' and
its partners' research and development activities of Cytokinetics’
product candidates and preparations for the potential
commercialization of tirasemtiv. Such statements are based on
management's current expectations, but actual results may differ
materially due to various risks and uncertainties, including, but
not limited to the risks related to Cytokinetics' business outlined
in Cytokinetics' filings with the Securities and Exchange
Commission. Forward-looking statements are not guarantees of future
performance, and Cytokinetics' actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in this press
release speak only as of the date of this press release.
Cytokinetics assumes no obligation to update its forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Contact:CytokineticsDiane WeiserVice President, Corporate
Communications, Investor Relations(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024